- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Daily Derm Times: July 2, 2025
Author(s):
Key Takeaways
- Regenerative aesthetics, such as exosome-powered skincare, offer long-lasting benefits, leading to increased patient preference over quick fixes.
- The ADmirable trial assesses lebrikizumab's safety and efficacy in patients with moderate to severe atopic dermatitis and pigmented skin.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Journal Digest: July 2, 2025
This review of the latest dermatologic studies includes insights into effectiveness and cost-effectiveness of treatments for psoriasis, bubble hair deformity induced by bathroom heating lamp, and more.
Why Patients Are Choosing Regenerative Aesthetics Over Quick Fixes
Robin Smith, MD, MBA, champions exosome-powered skincare for long-lasting skin health and personalized regenerative aesthetics solutions for patients.
Q&A Part 2: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD
Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.
E-Learning Boosts OCT Training for BCC Detection
E-learning enhances skin cancer detection by training professionals in OCT for accurate differentiation between basal cell carcinoma and non-BCC lesions.
New Research Highlights Zabalafin Hydrogel's Novel Multi-Targeted Approach to AD Treatment
A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multi-target therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
